Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403169 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00403169 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 28 participants.
The verdict
NCT00403169, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403169
The ClinicalTrials.gov registry entry for NCT00403169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT00403169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403169 about?
NCT00403169 is a clinical study titled "Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer". RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
What is the current status of trial NCT00403169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2004-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00403169?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00403169?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.